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Abstract
Background: Cardiac tamponade is a life-threatening state that complicates various medical 
conditions. The contemporary interventional era may have led to changes in clinical charac-
teristics, causes and outcomes of cardiac tamponade.
Methods: We investigated all patients diagnosed with cardiac tamponade, based on clinical 
and echocardiographic findings, at a single medical center between the years 2000 and 2013. 
Data on medical history, index hospitalizations, pericardial fluid etiologies, and acute and 
long-term outcomes were collected.
Results: Cardiac tamponade was observed in 83 patients (52% females). Major etiologies in-
cluded complications of percutaneous cardiac interventions (36%) and malignancies (primar-
ily lung cancer; 23%), infectious/inflammatory causes (15%) and mechanical complications 
of myocardial infarction (12%). Sixteen (19%) patients died during the index hospitalization. 
Acute presentation of symptoms and lower quantity of effusion were associated with in-hospital 
mortality (p = 0.045 and p = 0.007). Tamponade secondary to malignancy was associated with 
the most substantial increment in post-discharge mortality (from 16% in-hospital to 68% 1-year 
mortality). During the mean follow-up of 45 months, 39 (45%) patients died. Malignancies,  
mechanical complications of myocardial infarction and bleeding/coagulation abnormalities 
were etiologies associated with poor survival (80% mortality during follow-up). Tamponade 
secondary to complications of percutaneous cardiac interventions or infectious/inflammatory 
causes were associated with significantly lower mortality (28% and 17%; log rank p < 0.001).
Conclusions: In a contemporary cohort, complications of percutaneous cardiac intervention 
replaced malignant diseases as the leading cause of cardiac tamponade. Nevertheless, these 
iatrogenic complications were associated with a relatively favorable outcome compared to 
tamponade induced by complications of myocardial infarction, coagulation abnormalities and 
malignant diseases. (Cardiol J 2016; 23, 1: 57–63)
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Introduction
Cardiac tamponade is the accumulation of fluid 
in the pericardial space, leading to rapid fall in car-
diac output, hypotension and systemic hypoperfu-
sion [1]. Cardiac tamponade is a life-threatening 
condition that requires immediate intervention [1]. 
The clinical presentation is influenced by the rate 
at which pericardial fluid accumulates, deriving 
from the specific etiology of the tamponade [2]. 
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Cardiac tamponade occurs in diverse clinical situ-
ations, including complications of both acute and 
chronic medical conditions, as well as iatrogenic 
complications of surgical and percutaneous cardiac 
interventional procedures [3]. Presentation may 
be rapid: after chest wall trauma, after aortic or 
cardiac rupture, or due to complications of cardiac 
procedures, necessitating prompt diagnosis and 
treatment. However, complications of medical con-
ditions such as infections, metastatic malignancies, 
connective tissue diseases, uremia, hypothyroid-
ism or drug side effects, can be associated with 
pericarditis or pericardial effusion, which may 
progress more gradually to overt tamponade [3].
In recent years, applications of interven-
tional cardiovascular diagnostic and therapeutic 
procedures have increased, with the introduction 
of new and complex technologies for structural 
heart disease and electrophysiology [4, 5]. The 
use of antiplatelets and anticoagulation in clinical 
medicine is also expanding. On the other hand, 
traditional etiologies of pericarditis, such as tuber-
culosis, are decreasing in western societies. These 
developments may have conceivably changed the 
characteristics and implications of cardiac tampon-
ade in clinical medicine. Accordingly, the aim of the 
current study was to evaluate the clinical presenta-
tion, causes, and short- and long-term outcomes of 
cardiac tamponade, in a cohort of medical patients 
representing the contemporary interventional era.
Methods
Study cohort
The study population included all consecutive 
patients diagnosed with a first episode of cardiac 
tamponade during hospitalization at a single uni-
versity affiliated medical center (Carmel Medical 
Center, Haifa, Israel), between the years 2000 
and 2013. Tamponade cases secondary to cardiac 
surgery or chest-wall trauma were excluded from 
the cohort.
Baseline characteristics including demographic 
and clinical data, comorbidities, blood tests re-
sults and echocardiographic parameters were 
documented for all patients. Cardiac tamponade 
was diagnosed based on customary echocardio-
graphic evidence of tamponade physiology, such 
as right ventricular diastolic collapse, in addition 
to documented clinical evidence of tamponade 
or hemodynamic failure. All patients underwent 
pericardiocentesis or urgent surgery. Patients’ 
electronic files were reviewed retrospectively for 
documentation of the clinical presentation of the 
cardiac tamponade, usage of anticoagulants and the 
probable underlying etiologies.
The incidence of cardiac tamponade complicat-
ing percutaneous coronary and valvular interven-
tions was calculated by analyzing the computerized 
database of the cardiac catheterization unit. In 
addition, we have estimated the total number of 
electrophysiologic interventional procedures per-
formed during the study period, as no computerized 
data were available regarding the volume of these 
procedures during the initial years of the study.
Symptomatic presentation was classified as 
acute (symptoms at the day of tamponade presenta-
tion), subacute (1–7 days) or chronic (more than 
a week before tamponade presentation). Pericardial 
effusion quantity, as estimated by echocardiography 
during tamponade diagnosis, and quantification of 
the pericardial fluid drained, were noted.
Mortality during index hospitalization, as well 
as 30-day and 1-year mortality, were ascertained 
through July 2014 for all subjects, by reviewing 
computerized records of the health maintenance 
organization. The study protocol was approved 
by the Lady Davis Carmel Medical Center (Haifa, 
Israel) Institutional Review Board.
Statistical analysis
Continuous data are presented as mean ± stan - 
dard deviation (SD) and categorical variables as 
numbers and percentages. The independent-
samples T-test was used to compare continuous 
variables, and the c2 test was used to compare cat-
egorical variables. Fisher’s exact test was used in 
cases of small sample sizes. Survival curves were 
plotted for each of the main tamponade etiologies 
by the Kaplan-Meier method using the log-rank 
test for comparison between variables.
The results were considered statistically 
significant when the 2-sided p-value was < 0.05. 
SPSS statistical software version 20.0 was used to 
perform all statistical analyses.
Results
Eighty-three consecutive patients diagnosed 
with a first episode of cardiac tamponade during the 
years 2000 to 2013 were included in the analysis 
after exclusion of tamponade cases secondary to 
cardiac surgery or chest-wall trauma. Mean age 
of the study population was 67 ± 17 years, and 
52% were females. Baseline characteristics are 
presented in Table 1. Preserved left ventricular 
ejection fraction was noted in 52 (63%) patients. 
Acute presentation of symptoms was present in 
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44 (53%). The majority of patients (96%) were 
treated by pericardiocentesis. The volume of ef-
fusion drained ranged from 15 mL to 3 L (median 
600 mL), and 13 (16%) patients required blood 
product transfusions.
Various etiologies contributing to tamponade 
episodes are presented in Table 2. Complications 
of cardiovascular percutaneous interventional 
procedures were the most common causes of tam-
ponade, observed in 29 (36%) patients, including 
complications of percutaneous coronary and val-
vular interventions as well as electrophysiological 
procedures.
A total of 22,910 percutaneous coronary and 
valvular procedures were performed between 
January 1, 2000, and December 31, 2013. Among 
them there were 11,699 therapeutic interventions, 
of which 21 were complicated by cardiac tampon-
ade (0.18%). In addition, the estimated number of 
electrophysiological procedures during this period 
was 3,920, of which 8 cases were complicated by 
cardiac tamponade (0.20%). We considered cardiac 
tamponade secondary to temporary wire extraction 
a coronary/valvular procedural complication.
Malignancies, primarily lung cancer, were 
the second leading etiology of cardiac tamponade 
(19 [23%] patients). Of the infectious/inflamma-
tory causes (12 [14.5%] patients), only 2 cases 
were secondary to a diagnosed bacterial infection. 
Acute myocardial infarction (MI) complications 
were present in 10 (12%) cases. Bleeding and 
coagulation disorders were additional notable 
causes. Five patients suffering from tamponade 
who were concomitantly treated with anticoagula-
tion (warfarin), presented with severely abnormal 
coagulation tests (international normalized ratio 
levels 6.3–23), suggesting bleeding as the direct 
cause of tamponade. In addition, of the 6 patients 
with tamponade occurring immediately after an 
extraction of a temporary intravenous pacemaker 
wire, 3 were treated with glycoprotein (GP) IIb/IIIa 
inhibitor (eptifibatide) adjacent to the event.
Acute presentation of symptoms was noted in 
all cases of tamponade secondary to MI complica-
Table 1. Baseline characteristics of the study 
patients.
Variable Number (%)  
or mean ± SD
Age 67.1 ± 16.8
Gender (female) 43 (52%)
Smoking 23 (28%)
Diabetes mellitus 30 (36%)
Hypertension 54 (65%)
Coronary artery disease 30 (36%)
Chronic obstructive  
pulmonary disease
7 (8%)
Chronic renal failure 16 (19%)
Known malignancy 16 (19%)
Creatinine [mg/dL] 1.40 ± 1.07
Urea [mg/dL] 59 ± 37
Hemoglobin [g/dL] 12.0 ± 1.8
Symptomatic presentation:
Acute 44 (53%)
Subacute 34 (41%)
Chronic 5 (6%)
Pericardial effusion quantity  
(estimation by echo):
Mild 5 (6%)
Mild-moderate 6 (7%)
Moderate 12 (14%)
Moderate-large 4 (5%)
Large 45 (57%)
Unknown 9 (11%)
Table 2. Etiologies of cardiac tamponade.
Tamponade etiology Number (%)
Cardiac percutaneous interventional complications:
PCI complications 12 (14.5%)
TAVR/BAV complications 3 (4%)
Pacemaker insertion/ablation 
complications:
14 (17%)
Permanent pacemaker/ICD  
implantation
6
Temporary pacemaker  
electrode extraction
6
Radiofrequency ablation 2
Malignancy: 19 (23%)
Lung 11
Breast 2
Lymphoma 1
Other/unknown origin  5
Infectious/inflammatory: 12 (14.5%)
Bacterial infection 2
Acute myocardial infarction  
complications
10 (12%)
Unknown/idiopathic 8 (10%)
Bleeding/coagulation  
abnormalities
5 (6%) 
BAV — balloon aortic valvuloplasty; ICD — implantable cardioverter 
defibrillator; PCI — percutaneous coronary intervention; TAVR — 
trans-aortic valve replacement
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tions and in 93% of complications of percutane-
ous cardiac interventions. In addition, acute or 
subacute presentation was reported in all cases 
of tamponade secondary to bleeding/coagulation 
abnormalities. In contrast, 81% of patients with 
malignancy associated with cardiac tamponade had 
subacute or chronic presentation of symptoms.
During the index hospitalization, the all-cause 
mortality rate was 19% (16 patients). In-hospital 
mortality was associated with acute presentation of 
symptoms and smaller quantity of pericardial effu-
sion drained, but was not associated with common 
comorbidities (Table 3). The 30-day mortality rate 
was 24 (29%) patients. During a mean follow-up 
period of 45 ± 50 months (median 30 months), 
a total of 39 (47%) patients died.
Short- and long-term mortality rates, accord-
ing to the various causes of cardiac tamponade, 
are presented in Figure 1. Complications of acute 
MI and bleeding or coagulation disorders were the 
causes associated with the worst survival (80% 
1-year mortality). Tamponade secondary to malig-
nancies was associated with the most substantial 
increase in post-discharge mortality (from 16% 
in-hospital to 68% 1-year mortality). Cardiac tam-
ponade cases without any known identified etiology 
were evident in 8 patients, and were not associated 
with mortality events during follow-up. Cumula-
tive survival rates are presented in Figure 2, dif-
ferentiating between etiologies associated with 
very poor as opposed to better long-term survival. 
The log-rank test p-value for the overall compari-
son between tamponade etiologies was < 0.001. 
In addition, patients with tamponade secondary to 
complications of percutaneous cardiac interven-
tions had significantly better long-term survival 
than each of the 3 etiologies associated with poor 
survival (bleeding/coagulation abnormalities, ma-
lignancies, and MI complications); log-rank p < 0.01 
for each pairwise comparison.
Discussion
The present study, which comprised a contem-
porary cohort, revealed iatrogenic complications of 
percutaneous cardiac procedures to be the most 
prevalent etiology for cardiac tamponade. This find-
ing contrasts with previous clinical studies, which 
reported malignant diseases as the most common 
cause of pericardial tamponade, reaching 30–60% 
of cases [6–11]. This shift in tamponade etiology 
is apparently due to the increase in recent years 
in the overall number and in the complexity of 
percutaneous intra-cardiac procedures, as well as 
the introduction of interventional techniques such 
as trans-catheter valve replacement and catheter 
ablation for atrial fibrillation, all reported to be pos-
sibly complicated by cardiac tamponade [12–15].
In the current study, 0.18% of percutaneous 
coronary and valvular interventions were compli-
cated by cardiac tamponade. This is in accordance 
with recent data reporting an incidence of tampon-
Table 3. Association of baseline characteristics with in-hospital mortality.
Variable Alive (n = 67) In-hospital mortality (n = 16) P 
Age 67 ± 18 69 ± 13 0.548
Gender (female) 36 (54%) 7 (44%) 0.581
Smoking 20 (30%) 3 (19%) 0.537
Diabetes mellitus 26 (39%) 4 (25%) 0.392
Hypertension 44 (66%) 10 (63%) 0.812
Coronary artery disease 24 (36%) 6 (38%) 0.900
Chronic renal failure 11 (16%) 5 (31%) 0.287
Known malignancy 14 (21%) 2 (13%) 0.725
Moderate/severe reduced LVEF 6 (9%) 2 (25%) 0.215
Blood product transfusion 12 (18%) 1 (7%) 0.267
Acute presentation of symptoms 32 (48%) 12 (75%) 0.045
Creatinine [mg/dL] 1.39 ± 1.16 1.44 ± 0.48 0.783
Urea [mg/dL] 57 ± 36 68 ± 42 0.375
Hemoglobin [g/dL] 11.9 ± 1.9 12.5 ± 1.6 0.184
Effusion quantity [mL] 815 ± 602 356 ± 333 0.007
LVEF — left ventricular ejection fraction
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ade complicating percutaneous coronary interven-
tions ranging 0.036–0.38% in several previously 
published series [13]. The incidence of cardiac 
tamponade complicating electrophysiological pro-
cedures is less comparable due to the variability 
in type and complexity of procedures performed 
at different centers. Some technically demanding 
procedures such as atrial fibrillation ablation are 
associated with higher rates of tamponade, and 
were not performed in our center [12].
Despite its being the main etiology, iatrogenic 
cardiac tamponade secondary to percutaneous car-
diac procedures showed relatively low in-hospital 
and post hospitalization mortality, probably due to 
prompt diagnosis and treatment of these condi-
tions. On the other hand, the highest mortality 
rates, both during hospitalization and after, were 
among tamponade cases secondary to mechanical 
complications of acute MI. An example is free wall 
rupture, a fatal complication that has decreased in 
Figure 2. Long-term survival, according to cardiac tamponade etiologies.
Figure 1. Mortality rates according to different causes of cardiac tamponade.
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frequency in the percutaneous coronary revascu-
larization era.
The origins of malignant pericardial effusions 
include solid tumors and hematological malignan-
cies. Similar to our population, lung cancer was the 
most common origin of the malignant processes 
reported in studies summarizing clinical outcomes 
of malignant effusions [6, 8]. The mortality pattern 
of patients with malignancy-induced tamponade 
showed a low in-hospital rate, with progressive in-
crement during the year after the event. This may 
be attributable to the more gradual accumulation of 
the malignant effusion, which reduces the risk for 
a life threatening presentation, and enables treating 
the tamponade while the basic malignant disease 
advances. Similar outcomes have been shown in 
other studies that reported very low 1-year sur-
vival rates, ranging from 10% to 27% in malignant 
pericardial effusion [6, 16]. Accordingly, malignancy 
induced tamponade may indicate an ominous sign 
of advanced cancer.
The clinical indications for antiplatelet and 
anticoagulant therapy have expanded in recent 
years. Poor anticoagulation control, as seen in sev-
eral patients in the current study, may precipitate 
the development of hemopericardium, and is well 
documented in the literature as a possible cause 
of tamponade [17, 18]. In addition, an increasing 
number of patients are treated nowadays by novel 
oral anticoagulants (NOACs), for which assays to 
monitor the coagulation status are not yet com-
monly available. This may expose patients to life-
threatening bleeding, including pericardial effusion, 
which was recently reported in patients receiving 
NOACs [19, 20].
The use of adjuvant therapy with platelet 
GP IIb/IIIa inhibitors in patients with acute coro-
nary syndromes has increased markedly prior to 
complex coronary interventions, and is another 
possible contributor to tamponade in cases of coro-
nary perforation. In the current study, we report 
on 3 cases in which cardiac tamponade occurred 
following extraction of intravenous temporary 
pacing wire in patients who received GP IIb/IIIa 
inhibitors after invasive cardiac procedures. In 
these cases, the removal of the temporary pacing 
wire probably exposed the right ventricular per-
foration site, which led to the cardiac tamponade. 
Such cases, although rarely reported in the litera-
ture, might not be uncommon, and highlight the 
importance of careful management of patients with 
temporary pacing wires, including avoidance of 
frequent lead repositioning, usage of balloon-tipped 
pacing wires, monitoring arterial blood pressure 
for hemodynamic collapse, and accounting for the 
elimination half time of the GP IIb/IIIa inhibitor 
antiplatelet agent before removal of the temporary 
pacing wire [21, 22].
Limitations of the study
Potential limitations of the current study in-
clude the relatively low number of tamponade cases 
and the retrospective design. Moreover, the study 
population represents a single medical center, lim-
iting the generalization of the results. In addition, 
except for fluid quantity, we did not analyze the 
characteristics of the pericardial effusion and the 
diagnostic evaluation process, due to incomplete 
documentation of data in patients’ medical records.
Conclusions
In conclusion, pericardial tamponade derives 
from a wide range of etiologies with variable clini-
cal outcomes. In a contemporary cohort of medical 
patients, complications of percutaneous cardiac 
interventions replaced malignant diseases as the 
leading cause of cardiac tamponade. Nevertheless, 
these iatrogenic procedural complications were 
associated with relatively favorable in-hospital and 
1-year outcome. Traditional causes of tamponade, 
such as complications of acute MI and malignant 
diseases, continue to be associated with poor 
outcome, as does tamponade associated with the 
usage of antiplatelet and anticoagulant therapies. 
The frequency of the latter may rise consequently 
to the expanding clinical indications and the grow-
ing number and complexity of percutaneous cardiac 
interventions.
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